Cover Image
市場調查報告書

脂肪肝病:開發平台分析

Fatty Liver Disease - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 232847
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
脂肪肝病:開發平台分析 Fatty Liver Disease - Pipeline Review, H2 2015
出版日期: 2015年09月23日 內容資訊: 英文 148 Pages
簡介

所謂脂肪肝病是指肝臟細胞屯積脂肪的狀態,其代表性的原因有過度攝取酒精等。脂肪肝病的症狀有腹部膨脹、敏感性肌膚、嘔吐、吐血或便血、記憶混亂(失憶)、肌肉疲勞、黃膽等。

本報告提供全球脂肪肝病治療藥的開發中產品概要,提供您產品開發,上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

脂肪肝病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

脂肪肝病:企業開發中的治療藥

脂肪肝病:大學/機關研究中的治療藥

脂肪肝病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

脂肪肝病:企業開發中的產品

脂肪肝病:大學/機關研究中的產品

脂肪肝病的治療藥開發作的企業

  • Arisaph Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Conatus Pharmaceuticals Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dimerix Bioscience Pty Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Galmed International Ltd.
  • Generon (Shanghai) Corporation Ltd.
  • Genovate Biotechnology Co., LTD.
  • Gilead Sciences, Inc.
  • Huons Co., Ltd.
  • kyorin製藥
  • Metabolic Solutions Development Company, LLC
  • Nimbus Therapeutics, LLC
  • Novartis AG
  • Protalix BioTherapeutics, Inc.
  • Raptor Pharmaceuticals Corp.
  • Sancilio & Company, Inc.
  • TCM Biotech International Corp
  • Tobira Therapeutics, Inc.
  • Verva Pharmaceuticals Limited
  • Viking Therapeutics, Inc.
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

脂肪肝病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Aramchol
  • ARI-3037MO
  • C-10
  • CCX-872
  • cenicriviroc mesylate
  • cysteamine DR
  • DMX-300
  • 消化管·代謝性疾病ABHD6抑制劑
  • DUR-928
  • DWP-10292
  • emricasan
  • etanercept biosimilar
  • F-652
  • HU-002
  • KDT-501
  • MAT-8800
  • MB-12066
  • methazolamide
  • MN-002
  • MSDC-0602
  • MT-2
  • NDI-010976
  • norursodeoxycholic acid
  • oltipraz
  • PCBB-7
  • pradigastat sodium
  • Px-102
  • Px-103
  • Px-104
  • 動脈粥狀硬化性心血管疾病·肝脂肪變性基因改造蛋白質
  • RT-230
  • saroglitazar
  • SC-410
  • 脂肪肝病小分子
  • 循環系統系·消化管·代謝性疾病IKK·TBK1阻礙小分子
  • 代謝性·免疫性·消化管疾病Them1阻礙小分子
  • 脂肪肝病AMPK活躍小分子
  • 代謝性疾病NaCT阻礙小分子
  • 循環系統系·消化管·代謝性疾病·感染疾病合成胜肽
  • TCM-606F
  • VK-2809
  • VVP-100-X
  • ZGN-839

脂肪肝病:最近的開發平台趨勢

脂肪肝病:暫停中的計劃

脂肪肝病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7088IDB

Summary

Global Markets Direct's, 'Fatty Liver Disease - Pipeline Review, H2 2015', provides an overview of the Fatty Liver Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fatty Liver Disease Overview
  • Therapeutics Development
    • Pipeline Products for Fatty Liver Disease - Overview
    • Pipeline Products for Fatty Liver Disease - Comparative Analysis
  • Fatty Liver Disease - Therapeutics under Development by Companies
  • Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes
  • Fatty Liver Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fatty Liver Disease - Products under Development by Companies
  • Fatty Liver Disease - Products under Investigation by Universities/Institutes
  • Fatty Liver Disease - Companies Involved in Therapeutics Development
    • Arisaph Pharmaceuticals, Inc.
    • ChemoCentryx, Inc.
    • Conatus Pharmaceuticals Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Dimerix Bioscience Pty Ltd
    • Dr. Falk Pharma GmbH
    • DURECT Corporation
    • Galmed International Ltd.
    • Generon (Shanghai) Corporation Ltd.
    • Genovate Biotechnology Co., LTD.
    • Gilead Sciences, Inc.
    • Huons Co., Ltd.
    • Kyorin Pharmaceutical Co., Ltd.
    • Metabolic Solutions Development Company, LLC
    • Nimbus Therapeutics, LLC
    • Novartis AG
    • Protalix BioTherapeutics, Inc.
    • Raptor Pharmaceuticals Corp.
    • Sancilio & Company, Inc.
    • TCM Biotech International Corp
    • Tobira Therapeutics, Inc.
    • Verva Pharmaceuticals Limited
    • Viking Therapeutics, Inc.
    • Zafgen Inc.
    • Zydus Cadila Healthcare Limited
  • Fatty Liver Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Aramchol - Drug Profile
    • ARI-3037MO - Drug Profile
    • C-10 - Drug Profile
    • CCX-872 - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • cysteamine DR - Drug Profile
    • DMX-300 - Drug Profile
    • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
    • DUR-928 - Drug Profile
    • DWP-10292 - Drug Profile
    • emricasan - Drug Profile
    • etanercept biosimilar - Drug Profile
    • F-652 - Drug Profile
    • HU-002 - Drug Profile
    • KDT-501 - Drug Profile
    • MAT-8800 - Drug Profile
    • MB-12066 - Drug Profile
    • methazolamide - Drug Profile
    • MN-002 - Drug Profile
    • MSDC-0602 - Drug Profile
    • MT-2 - Drug Profile
    • NDI-010976 - Drug Profile
    • norursodeoxycholic acid - Drug Profile
    • oltipraz - Drug Profile
    • PCBB-7 - Drug Profile
    • pradigastat sodium - Drug Profile
    • Px-102 - Drug Profile
    • Px-103 - Drug Profile
    • Px-104 - Drug Profile
    • Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile
    • RT-230 - Drug Profile
    • saroglitazar - Drug Profile
    • SC-410 - Drug Profile
    • Small Molecule for Fatty Liver Disease - Drug Profile
    • Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
    • Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases - Drug Profile
    • Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
    • Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
    • Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile
    • TCM-606F - Drug Profile
    • VK-2809 - Drug Profile
    • VVP-100-X - Drug Profile
    • ZGN-839 - Drug Profile
  • Fatty Liver Disease - Recent Pipeline Updates
  • Fatty Liver Disease - Dormant Projects
  • Fatty Liver Disease - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fatty Liver Disease, H2 2015
  • Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Fatty Liver Disease - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by ChemoCentryx, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015
  • Fatty Liver Disease - Pipeline by Dr. Falk Pharma GmbH, H2 2015
  • Fatty Liver Disease - Pipeline by DURECT Corporation, H2 2015
  • Fatty Liver Disease - Pipeline by Galmed International Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Genovate Biotechnology Co., LTD., H2 2015
  • Fatty Liver Disease - Pipeline by Gilead Sciences, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Huons Co., Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015
  • Fatty Liver Disease - Pipeline by Nimbus Therapeutics, LLC, H2 2015
  • Fatty Liver Disease - Pipeline by Novartis AG, H2 2015
  • Fatty Liver Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Raptor Pharmaceuticals Corp., H2 2015
  • Fatty Liver Disease - Pipeline by Sancilio & Company, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by TCM Biotech International Corp, H2 2015
  • Fatty Liver Disease - Pipeline by Tobira Therapeutics, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Verva Pharmaceuticals Limited, H2 2015
  • Fatty Liver Disease - Pipeline by Viking Therapeutics, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Zafgen Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Fatty Liver Disease Therapeutics - Recent Pipeline Updates, H2 2015
  • Fatty Liver Disease - Dormant Projects, H2 2015
  • Fatty Liver Disease - Dormant Projects (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Fatty Liver Disease, H2 2015
  • Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top